{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:40:08Z","timestamp":1777426808035,"version":"3.51.4"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium falciparum<\/jats:named-content>malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. falciparum<\/jats:named-content>transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydroartemisinin-piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroartemisinin-piperaquine (120\/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>), area under the concentration-time curve from 0 h to the end of the study (AUC<jats:sub>0\u2013last<\/jats:sub>), and area under the concentration-time curve from 0 h to infinity (AUC<jats:sub>0\u2013\u221e<\/jats:sub>) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.)<\/jats:p>","DOI":"10.1128\/aac.03704-14","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T02:09:54Z","timestamp":1412042994000},"page":"7340-7346","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects"],"prefix":"10.1128","volume":"58","author":[{"given":"Borimas","family":"Hanboonkunupakarn","sequence":"first","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Ashley","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Podjanee","family":"Jittamala","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasithon","family":"Pukrittayakamee","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warunee","family":"Hanpithakpong","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palang","family":"Chotsiri","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaporn","family":"Wattanakul","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwaluk","family":"Panapipat","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Updated WHO policy recommendation (October 2012): single dose primaquine as a gametocytocide in Plasmodium falciparum malaria","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Updated WHO policy recommendation (October 2012): single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.","edition":"2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-418"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70079-7"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-12"},{"key":"e_1_3_2_7_2","volume-title":"Country antimalarial drug policies: by region","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. December 2012. Country antimalarial drug policies: by region. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/malaria\/am_drug_policies_by_region_searo\/en\/."},{"key":"e_1_3_2_8_2","volume-title":"Country antimalarial drug policies: by region","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. December 2012. Country antimalarial drug policies: by region. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/malaria\/am_drug_policies_by_region_wpro\/en\/."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05685.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0656-1"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00927-08"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.10.018"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.12.011"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02794-13"},{"key":"e_1_3_2_15_2","volume-title":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products","author":"US Food and Drug Administration","year":"2003","unstructured":"US Food and Drug Administration. 2003. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products. U.S. Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2407-2411.2005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.79.620"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00279-11"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02318-13"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.951"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2009.09-0214"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0022-3565(25)00083-7","article-title":"The acute joint toxicity of atabrine, quinine, hydroxyethylapocupreine, pamaquine and pentaquine","volume":"91","author":"Chen G","year":"1947","unstructured":"ChenGGeilingEM. 1947. The acute joint toxicity of atabrine, quinine, hydroxyethylapocupreine, pamaquine and pentaquine. J. Pharmacol. Exp. Ther. 91:133\u2013139.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI101947"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9102-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02709.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-259"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2009.07.012"},{"key":"e_1_3_2_28_2","volume-title":"Eurartesim: EPAR\u2013product information","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency. 2012. Eurartesim: EPAR\u2013product information. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001199\/WC500118113.pdf."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05756-11"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.9.1005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01717-08"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/379714"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01962.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.447"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03704-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03704-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T22:39:18Z","timestamp":1746398358000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03704-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1128\/AAC.03704-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03704-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}